Drug research

Resmetirom

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as MGL-3196

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)NCT04951219	MDGL	Phase 3	Active not recruiting	2027-03Estimated
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHNCT07335601	MDGL	Phase 2	Recruiting	2028-08Estimated
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsNCT04197479	MDGL	Phase 3	Completed	2023-01-06Actual
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)NCT05500222	MDGL	Phase 3	Active not recruiting	2026-12Estimated

MDGLActive not recruitingPrimary completion: 2027-03 · Estimated

Trial details

MDGLRecruitingPrimary completion: 2028-08 · Estimated

Trial details

MDGLCompletedPrimary completion: 2023-01-06 · Actual

Trial details

MDGLActive not recruitingPrimary completion: 2026-12 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.